Your browser doesn't support javascript.
loading
Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer.
Sena, Laura A; Fountain, Julia; Isaacsson Velho, Pedro; Lim, Su Jin; Wang, Hao; Nizialek, Emily; Rathi, Nityam; Nussenzveig, Roberto; Maughan, Benjamin L; Velez, Miguel Gonzalez; Ashkar, Ryan; Larson, Amanda C; Pritchard, Colin C; Adra, Nabil; Bryce, Alan H; Agarwal, Neeraj; Pardoll, Drew M; Eshleman, James R; Lotan, Tamara L; Antonarakis, Emmanuel S.
Afiliación
  • Sena LA; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Fountain J; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Isaacsson Velho P; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Lim SJ; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Wang H; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Nizialek E; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Rathi N; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Nussenzveig R; Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
  • Maughan BL; Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
  • Velez MG; Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
  • Ashkar R; Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, Arizona, USA.
  • Larson AC; Division of Hematology-Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Pritchard CC; Department of Laboratory Medicine, University of Washington, Seattle, Washington, USA.
  • Adra N; Department of Laboratory Medicine, University of Washington, Seattle, Washington, USA.
  • Bryce AH; Division of Hematology-Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Agarwal N; Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, Arizona, USA.
  • Pardoll DM; Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
  • Eshleman JR; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Lotan TL; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Antonarakis ES; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Oncologist ; 26(2): e270-e278, 2021 02.
Article en En | MEDLINE | ID: mdl-33215787

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Antineoplásicos Inmunológicos Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans / Male Idioma: En Revista: Oncologist Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Antineoplásicos Inmunológicos Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans / Male Idioma: En Revista: Oncologist Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido